What is the 13F Pro Quality Score for MNKD?

13F Pro ranks MANNKIND CORP (MNKD) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View MNKD's current score at https://13fpro.ai/research/MNKD (free sign-up required for the full ranking).

Which hedge funds own the most MNKD stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of MNKD include BlackRock,, STATE STREET, VANGUARD CAPITAL MANAGEMENT. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/MNKD as soon as new 13F filings post.

Where does 13F Pro source MNKD data?

All MANNKIND CORP fundamentals and ownership data come directly from SEC EDGAR. MANNKIND CORP files with the SEC under CIK 899460. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is MNKD in?

MANNKIND CORP (MNKD) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is MNKD research updated on 13F Pro?

MNKD's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

MANNKIND CORP(MNKD)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 899460 MNKD stock profile & AI dashboard →

13F Pro Quality Score

44.4/100

Rank #1,774 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

85.3/100

Profitability

30.6/100

Balance Sheet

40.4/100

Earnings Quality

30.0/100

Free Cash Flow

50.7/100

Institutional Flow

6.5/100

Revenue Scale

31.1/100

Dilution Risk

21.5/100

MNKD Stock Analysis & AI Quality Score

AI stock analysis and institutional research for MANNKIND CORP (MNKD), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores MNKD at 44.4/100 on a 32-signal composite quality model, placing it at rank #1,774 of 2,879 stocks — the bottom half of the AI-ranked universe. MNKD scores in the top quartile across revenue growth (85.3). Areas of concern include institutional flow (6.5) and earnings quality (30.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 21.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), MANNKIND CORP reports quarterly revenue of $90.2M, net income of $-16.6M, free cash flow of $-7.2M. Top institutional holders of MNKD by reported 13-F value include BlackRock,, STATE STREET, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. MNKD trades on the Nasdaq exchange and files with the SEC under CIK 899460. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MNKD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for MANNKIND CORP directly from SEC EDGAR. MANNKIND CORP's 13F Pro composite quality score has ranged between 8 and 87 since 2021, currently 44.4 — an improving long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about MANNKIND CORP

Quirks, history, and lore behind MNKD — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. biopharmaceutical company · small-cap · listed on Nasdaq · focused on diseases where drug delivery is as important as the drug itself.
2
The Numbers
Annual revenue in the low hundreds of millions of dollars, with a history of losses that would make even optimistic investors reach for an antacid — though the balance sheet has been slowly improving.
3
The History
Founded in 1991, the company spent years and enormous capital developing a technology to make insulin inhalable — a quest that attracted big pharma partners and then nearly bankrupted it when they walked away.
4
The Secret
Its core technology, called Technosphere, turns drug molecules into tiny particles that dissolve almost instantly in the lungs — delivering drugs to the bloodstream faster than an injection.
5
The Lore
Pfizer tried the same inhaled-insulin idea and pulled its own product off the market in 2007 after poor sales — yet this scrappy company kept going and eventually got its version, Afrezza, approved by the FDA in 2014.
6
The Giveaway
The only company selling inhaled insulin in the U.S., its founder shares a last name with a Nobel Prize-winning discovery — and the ticker cleverly echoes that very famous name in diabetes history.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$90.2M

Net Income

Q1 2026

$-16.6M

Free Cash Flow

Q1 2026

$-7.2M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+43.5% YoY

$285.5MFY 2024

FY21 $75.4MFY22 $99.8MFY23 $199.0MFY24 $285.5M

Net Income

+331.1% YoY

$27.6MFY 2024

FY21 $-80.9MFY22 $-87.4MFY23 $-11.9MFY24 $27.6M

Operating Income

+736.4% YoY

$72.6MFY 2024

FY21 $-47.0MFY22 $-64.1MFY23 $8.7MFY24 $72.6M

EPS (Diluted)

+350.0% YoY

$0.10FY 2024

FY21 $-0.32FY22 $-0.34FY23 $-0.04FY24 $0.10

Total Assets

-17.1% YoY

$393.8MFY 2024

FY21 $321.2MFY22 $295.3MFY23 $475.2MFY24 $393.8M

Total Debt

-86.6% YoY

$36.1MFY 2024

FY21 $281.2MFY22 $273.5MFY23 $268.7MFY24 $36.1M

Op. Cash Flow

+24.7% YoY

$42.5MFY 2024

FY21 $-61.7MFY22 $-80.7MFY23 $34.1MFY24 $42.5M

Metric	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Revenue	$285.5M +43.5%	$199.0M +99.4%	$99.8M +32.2%	$75.4M +15.8%	$65.1M +3.3%	$63.0M
Net Income	$27.6M +331.1%	$-11.9M +86.3%	$-87.4M -8.0%	$-80.9M -41.4%	$-57.2M -10.3%	$-51.9M
Operating Income	$72.6M +736.4%	$8.7M +113.5%	$-64.1M -36.3%	$-47.0M +1.9%	$-47.9M -7.4%	$-44.6M
EPS (Diluted)	$0.10 +350.0%	$-0.04 +88.2%	$-0.34 -6.3%	$-0.32 -23.1%	$-0.26	—
Total Assets	$393.8M -17.1%	$475.2M +60.9%	$295.3M -8.1%	$321.2M +195.7%	$108.6M +15.9%	$93.7M
Total Debt	$36.1M -86.6%	$268.7M -1.8%	$273.5M -2.7%	$281.2M +130.1%	$122.2M -1.4%	$123.9M
Operating Cash Flow	$42.5M +24.7%	$34.1M +142.3%	$-80.7M -30.7%	$-61.7M -119.4%	$-28.1M +68.2%	$-88.5M

AI Insight: MNKD Financial Trends

Revenue surged 45% to $112M in Q4 2025 but profitability collapsed as debt ballooned from $36M to $355M.

• Revenue jumped from $77M in Q2 2025 to $112M in Q4 2025, showing strong quarterly acceleration.

• Operating income turned negative at -$8M in Q4 2025 after posting positive margins through Q3 2025.

• Total debt exploded from $36M in Q2 2025 to $355M in Q4 2025, nearly 10x increase.

⚠ Operating cash flow volatility with -$8M in Q4 2025 after $24M positive in Q3 2025.

⚠ Revenue sustainability after Q1 2026 dropped to $90M from Q4 2025's $112M peak.

AI Insight: MNKD Ratio Trends

MANNKIND's profitability collapsed in the latest quarters, with operating margin turning negative to -1.8% in Q1 2026 after peaks of 34.5% in Q4 2024.

• Operating margin plummeted from 34.5% in Q4 2024 to -1.8% in Q1 2026, marking sharp deterioration.

• Net profit margin fell from 16.8% in Q1 2025 to -18.4% in Q1 2026.

• ROA declined from 12.8% in Q1 2025 to -8.9% in Q1 2026.

• ROIC turned negative to -2.6% in Q1 2026 from positive 5.7% TTM performance.

⚠ Extreme margin volatility suggests unstable operating performance requiring close monitoring of revenue sustainability.

⚠ Two consecutive quarters of negative operating margins signal potential operational challenges.

Get alerted when MNKD's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for MANNKIND CORP including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of MNKD

BlackRock, Inc.
$70.1M28,600,998 sh
STATE STREET CORP
$45.8M18,683,483 sh
VANGUARD CAPITAL MANAGEMENT LLC
$31.6M12,891,066 sh
UBS Group AG
$20.2M8,255,430 sh
GEODE CAPITAL MANAGEMENT, LLC
$18.4M7,505,147 sh
MILLENNIUM MANAGEMENT LLC
$15.7M6,390,922 sh
Frazier Life Sciences Management, L.P.
$14.5M5,900,000 sh
MORGAN STANLEY
$14.2M5,793,147 sh
DIMENSIONAL FUND ADVISORS LP
$12.1M4,953,295 sh
180 WEALTH ADVISORS, LLC
$10.5M4,291,703 sh

Fund	Value	Shares
BlackRock, Inc.	$70.1M	28,600,998
STATE STREET CORP	$45.8M	18,683,483
VANGUARD CAPITAL MANAGEMENT LLC	$31.6M	12,891,066
UBS Group AG	$20.2M	8,255,430
GEODE CAPITAL MANAGEMENT, LLC	$18.4M	7,505,147
MILLENNIUM MANAGEMENT LLC	$15.7M	6,390,922
Frazier Life Sciences Management, L.P.	$14.5M	5,900,000
MORGAN STANLEY	$14.2M	5,793,147
DIMENSIONAL FUND ADVISORS LP	$12.1M	4,953,295
180 WEALTH ADVISORS, LLC	$10.5M	4,291,703

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put MNKD on your watchlist

Track score changes the day MANNKIND CORP files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is MNKD a good stock to buy?

13F Pro's AI-powered analysis of MANNKIND CORP (MNKD) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for MNKD are available on the MNKD stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own MNKD?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling MNKD. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of MANNKIND CORP's investment landscape.